Dr. Theresa M. Medina
Claim this profileUniversity of Colorado Hospital
Expert in Melanoma
Studies Cancer
19 reported clinical trials
26 drugs studied
About Theresa M. Medina
Education:
- Obtained MD from the University of Colorado School of Medicine in 2015.
- Completed Residency in Internal Medicine at the University of Colorado Hospital in 2018.
- Finished Fellowship in Hematology/Oncology at the University of Colorado Hospital in 2021.
Experience:
- Currently serves as a Hematology and Oncology specialist at the University of Colorado Hospital.
Area of expertise
1Melanoma
Global LeaderStage IV
Stage III
BRAF positive
2Cancer
Stage IV
BRAF positive
Stage III
Affiliated Hospitals
Clinical Trials Theresa M. Medina is currently running
Brentuximab Vedotin + Pembrolizumab
for Advanced Cancers
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
Recruiting1 award Phase 27 criteria
DEC-C + Nivolumab
for Melanoma
Activation of the RIG-I innate immune pathway and increased expression of tumor antigens and pro-immune genes by DEC-C during Nivolumab treatment may enhance the frequency and activity of anti-tumor immune cells (CD4+ and CD8+ T-cells, NK cells) and reduce the frequency and activity of immunosuppressive cells. This may increase the overall effectiveness and success of Nivolumab treatment. This pilot clinical trial will demonstrate whether combinatorial immunotherapeutic approaches that target epigenetic immune repression and RIG-I activity can favorably alter the tumor immune cell microenvironment and benefit patients with mucosal melanoma.
Recruiting1 award Phase 1 & 215 criteria
More about Theresa M. Medina
Clinical Trial Related4 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Theresa M. Medina has experience with
- Nivolumab
- Pembrolizumab
- Ipilimumab
- TSR-022
- Relatlimab
- RP1
Breakdown of trials Theresa M. Medina has run
Melanoma
Cancer
Tumors
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Theresa M. Medina specialize in?
Theresa M. Medina focuses on Melanoma and Cancer. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are Stage III.
Is Theresa M. Medina currently recruiting for clinical trials?
Yes, Theresa M. Medina is currently recruiting for 8 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Theresa M. Medina has studied deeply?
Yes, Theresa M. Medina has studied treatments such as Nivolumab, Pembrolizumab, Ipilimumab.
What is the best way to schedule an appointment with Theresa M. Medina?
Apply for one of the trials that Theresa M. Medina is conducting.
What is the office address of Theresa M. Medina?
The office of Theresa M. Medina is located at: University of Colorado Hospital, Aurora, Colorado 80045 United States. This is the address for their practice at the University of Colorado Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.